Jia Lu
10 Papers
7 Citations
Jia Lu is an academic researcher. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 2, co-authored 8 publications.
Chat about Author
Papers
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
Weiwei Wu,Tiongsun Chia,Jia Lu,Xue Li,Jian Guan,Yaning Li,Fenggen Fu,Shuaixiang Zhou,Ye Feng,Junjie Deng,Jia Zou,Jiya Sun,Ying Yao,Xiaomin Ling,Zhihai Wu,Ying Zhang,Jinling Xu,Feifei Wang,Xue Liang,Min Wu,Huisi Liu,Bing Chen,Kaijie He +22 more
TL;DR: It is shown that versions of IL-2 that preserve CD25 activity expand tumor-specific T cells more effectively than CD25-sparing agonists and find that the efficacy of anti-PD-1 depends on the activation of PD-1+CD25+ T cells through autocrine IL-1–CD25 signaling.
25
Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge
Ding Tang,Xiaoke K. Liu,Jia Lu,Huiying Fan,Xiuli Xu,Kaili Sun,Ruyu Wang,Chunyang Li,Demiao Dan,Zejun Wang,Xinguo Li,Xiaoming Yang +11 more
TL;DR: In this article , the immunogenicity of MPXV structural proteins such as A29L, M1R, A35R, and B6R was investigated in BALB/c mice.
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Xiaoman Li,Yongbing Pan,Qiangling Yin,Zejun Wang,Sisi Shan,Laixing Zhang,Jinfang Yu,Yuan-Qing Qu,Lina Sun,Fang Gui,Jia Lu,Zhaofei Jing,Wei Wu,Tao Huang,Xuanling Shi,Jiandong Li,Xinguo Li,Dexin Li,Shiwen Wang,Maojun Yang,Linqi Zhang,Kai Duan,Mifang Liang,Xiaoming Yang,Xinquan Wang +24 more
TL;DR: In this paper , the authors characterized the previously reported F61, which was isolated from convalescent patients infected with prototype SARS-CoV-2, as a broadly neutralizing antibody against all VOCs including Omicron BA.1, BA.2 and BA.4 sublineages by utilizing antigen binding and cell infection assays.
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Xiaoman Li,Yongbing Pan,Qiangling Yin,Zejun Wang,Sisi Shan,Laixing Zhang,Jinfang Yu,Yuan-Qing Qu,Lina Sun,Fang Gui,Jia Lu,Zhaofei Jing,Wei Wu,Tao Huang,Xuanling Shi,Jiandong Li,Xinguo Li,Dexin Li,Shiwen Wang,Maojun Yang,Linqi Zhang,Kai Duan,Mifang Liang,Xiao-Ming Yang,Xinquan Wang +24 more
TL;DR: In this article , the authors characterized the previously reported F61, which was isolated from convalescent patients infected with prototype SARS-CoV-2, as a broadly neutralizing antibody against all VOCs including Omicron BA.1, BA.2 and BA.4 sublineages by utilizing antigen binding and cell infection assays.
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
Changrui Lu,Yuntao Zhang,Xiaohu Liu,Fujun Hou,Rujie Cai,Zhibin Yu,Meilin Liu,Guohuan Yang,Jun Ding,Jiang Xu,Xianwu Hua,Xinping Pan,Lianxiao Liu,Kang Lin,Zejun Wang,Xinguo Li,Jia Lu,Qiu Zhang,Yuwei Li,Chunxia Hu,Huifeng Fan,Xiaoke K. Liu,Hui Wang,Rui Jia,F. Xu,Xue-Wei Wang,Hongwei Huang,Ronghua Zhao,Jing Li,Hang Cheng,William Jia,Xiaoming Yang +31 more
TL;DR: In this paper , two mRNA vaccines ZSVG-02 (Delta) and ZSVM-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV).
5